OXSORALEN® LOTION 1%
(Methoxsalen USP, 1%)
Each ml. of Oxsoralen Lotion contains 10 mg. methoxsalen in an inert vehicle containing alcohol (71% v/v), propylene glycol, acetone, and purified water. Methoxsalen is a naturally occurring substance found in the seeds of the Ammi majus (Umbelliferae) plant and in the roots of Heracleum Candicans. It belongs to a group of compounds known as psoralens or furocou-marins.
OXSORALEN (Methoxsalen TOPICAL) is indicated for the following:
As a topical repigmenting agent in vitiligo in conjunction with controlled doses of ultraviolet A (320-400 nm) or sunlight.
Media Articles Related to Oxsoralen (Methoxsalen Topical)
Arthritis drug could be used to treat vitiligo
Source: Dermatology News From Medical News Today [2015.06.26]
Researchers have discovered that tofacitinib, a drug normally used to treat rheumatoid arthritis, could restore pigmentation in people with vitiligo.
Drug for Rheumatoid Arthritis May Also Help Ease Vitiligo
Source: MedicineNet Arthritis Specialty [2015.06.25]
Title: Drug for Rheumatoid Arthritis May Also Help Ease Vitiligo
Category: Health News
Created: 6/24/2015 12:00:00 AM
Last Editorial Review: 6/25/2015 12:00:00 AM
Vitiligo: A Common Cause of Loss of Skin Pigment
Source: MedicineNet Vitiligo Specialty [2014.12.01]
Title: Vitiligo: A Common Cause of Loss of Skin Pigment
Category: Doctor's Views
Created: 6/2/2005 12:00:00 AM
Last Editorial Review: 12/1/2014 12:00:00 AM
Source: MedicineNet Achalasia Specialty [2014.11.01]
Category: Diseases and Conditions
Created: 7/11/1999 12:00:00 AM
Last Editorial Review: 11/1/2014 12:00:00 AM
Published Studies Related to Oxsoralen (Methoxsalen Topical)
Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for chronic plaque-type psoriasis. [2006.10]
BACKGROUND: Bath-psoralen plus ultraviolet A (PUVA) radiation therapy is increasingly replacing oral PUVA because of its superior short- and long-term safety profile. Several investigations in recent years have led to a refinement of the bath-PUVA protocol; however, the optimal therapeutic concentration of methoxsalen in the bath water has as yet not been delineated. OBJECTIVES: The therapeutic efficacy and tolerability of bath-PUVA by using two different dilutions of methoxsalen (1 mg/L vs 5 mg/L or 0.0001% vs 0.0005%) were compared in 46 patients with chronic plaque-type psoriasis in a prospective, randomized, double-blind study... CONCLUSIONS: Our data indicate that in bath-PUVA treatment the use of a high (5 mg/L) methoxsalen concentration is substantially more effective in clearing chronic plaque-type psoriasis than a low (1 mg/L) concentration.
Drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine. [2006.07]
Furanocoumarins increase the bioavailability of drugs that are CYP3A4 substrates. A possible interaction of methoxsalen with cyclosporine was evaluated in 12 healthy volunteers following oral administration of 40 mg methoxsalen, 200 mg cyclosporine, or a combination of both in a randomized crossover study...
Clinical Trials Related to Oxsoralen (Methoxsalen Topical)
A Safety and Efficacy Study of Uvadex and Extracorporeal Photopheresis (ECP) in Chronic Graft Versus Host Disease [Recruiting]
The purpose of this study is to evaluate the safety and effectiveness of extracorporeal
photopheresis therapy when added to standard drug therapies administered to patients with
moderate to severe chronic graft-versus-host disease.
Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis [Recruiting]
The purpose of this prospective, randomized, controlled, single-blinded investigation is to
study the efficacy, tolerability and safety of oral photochemotherapy (PUVA) combined with
acitretin versus oral PUVA combined with systemic fumaric acid esters (FAE) in patients with
pustular palmoplantar psoriasis.
Patients will be randomized and allocated in concealed manner to one of the two treatment
arms: acitretin-PUVA or FAE-PUVA.
RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART) [Recruiting]
The objectives of this clinical trial are to:
- Assess the safety of using extracorporeal photoimmune therapy with the photosensitizing
agent Uvadex in the treatment of HIV-1 infection;
- Evaluate the effects of this therapy on HIV-1 viral load by polymerase chain reaction
- Evaluate the effects of this therapy on CD4+, CD8+ cells and CD4/CD8 ratio;
- Evaluate the effects of this therapy on the patient's immune system, by skin reactivity
to a standard anergy panel.
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-Versus-Host Disease [Active, not recruiting]
The purpose of this study is to determine whether Extracorporeal Photopheresis with UVADEX
(ECP) prior to bone marrow or peripheral blood stem cell transplantation is effective in the
prevention of Graft-versus-Host Disease (GvHD).
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease [Active, not recruiting]
his study will explore the safety and activity of ECP treatment with UVADEX in inducing a
clinical response (i. e., a CDAI decrease greater than or equal to 100 from baseline and/or a
CDAI < 150) over a 12-week period in moderately active Crohn’s disease (CDAI greater than or
equal to 220 to < 450) patients who are refractory or intolerant to immunosuppressants and/or
anti-TNF agents. This study will also assess response to continued treatment during a
12-week Extension Period in patients who have a clinical response at Week 12 of the Treatment
Period and elect to participate in the Extension Period.